Otros idiomas Oculis Holding AG

Acciones

OCS

CH1242303498

Precio de cierre Nasdaq Otros sitios de cotización 00:00:00 13/05/2024			Varia. Cinco días.	Varia. 1 de enero.
12,07 ^USD	0,00 %		-5,04 %	+7,48 %

08/05	Oculis Holding AG informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
24/04	OCULIS HOLDING AG : HC Wainwright mantiene su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K	08/05
Oculis : Form 6-K	08/05
Oculis Reports Q1 2024 Financial Results and Provides Company Updates	08/05
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis	08/05
Oculis Publishes Invitation to the Annual General Meeting	07/05
Oculis to Present at Bank of America Global Healthcare Conference	06/05
Oculis Publishes Invitation to the Annual General Meeting	29/04
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	24/04
Oculis Completes $59 Million Direct Offering of Shares	22/04
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market	22/04
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market	11/04
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development	10/04
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	10/04
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	08/04
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	08/04
Oculis to Participate at Upcoming April Investor Conferences	04/04
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	01/04
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall	18/03
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress	18/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Oculis Holding AG

Acciones

OCS

CH1242303498

Otros idiomas

Filtros